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Hepatocellular carcinoma (HCC) is a leading
cause of cancer death worldwide [World
Health Organization (WHO) 2003], and a
heavy burden of HCC has been documented
in sub-Saharan Africa (Bah et al. 2001; Bosch
et al. 2005). Chronic infection with hepatitis B
virus (HBV) is endemic in sub-Saharan Africa,
and hepatitis C virus (HCV) infection is also
present (McMahon 2005; The Global Burden
of Hepatitis C Working Group 2004). Dietary
exposure to aﬂatoxin, primarily through inges-
tion of contaminated maize and groundnuts
(peanuts), is also widespread (Turner et al.
2005; Wild et al. 1993). Largely because of the
lack of clinical and research infrastructure, rig-
orous investigation into the etiology and
characteristics of chronic liver disease in sub-
Saharan Africa has been limited. Studies on
HCC are relatively rare, and controlled studies
on the etiology of cirrhosis have been reported
even less frequently (Lesi et al. 2002).
Worldwide, cirrhosis of the liver is the 16th
leading cause of death, responsible for hun-
dreds of thousands of deaths each year (WHO
2003). Cirrhosis onset is often asymptomatic or
associated with mild clinical symptoms, and
individuals with subclinical cirrhosis can lead
relatively normal lives for many years. Cirrhotic
persons, however, are at high risk for liver
decompensation and, irrespective of etiology,
have a high risk for development of HCC.
Diagnosis of cirrhosis, generally requiring
histopathologic review of a liver biopsy speci-
men, is infrequently performed in many
resource-constrained settings. In developed
countries, cirrhosis is associated with chronic
infection with HBV and HCV viruses (Corrao
et al. 1998; Tsai et al. 1994, 2003), excessive
use of alcohol (Corrao et al. 1998; Tsai et al.
2003), hereditary factors (Gershwin et al.
2005), obesity (Poonawala et al. 2000), smok-
ing (Tsai et al. 2003), and occupational expo-
sure to vinyl chloride (Mastrangelo et al. 2004),
but evaluation of potential interactions between
these risk factors are only beginning to be con-
ducted (Corrao et al. 1998; Mastrangelo et al.
2004). Additionally, it is not known whether
recognized etiologic factors for cirrhosis consti-
tute an exhaustive list or whether unidentiﬁed
etiologic agents remain. 
HCC most commonly occurs in cirrhotic
individuals (Chen et al. 2006; Takano et al.
1995). Risk factors for HCC have been
extensively studied, and in addition to the eti-
ologic factors for cirrhosis listed above, HCC
is also associated with aflatoxin exposure
[International Agency for Research on Cancer
(IARC) 1993; Qian et al. 1994]. Although
the biologic mechanisms that induce cirrhosis
and carcinogenesis are different, the consider-
able overlap in causative factors between cir-
rhosis and HCC suggests that factors that
have thus far only been linked to HCC may
also predispose to cirrhosis.
In this study, we investigated the diagnosis
of liver cirrhosis via a noninvasive, validated
ultrasound scoring system (Hung et al. 2003;
Lin et al. 1993) among individuals with sus-
pected liver disease in The Gambia, West
Africa. Then, in a case–control study design,
we examined environmental exposures for cir-
rhosis, including viral, dietary, and lifestyle
risk factors in this population. Finally, we
explored interactions between HBV and aﬂa-
toxin exposure to more precisely describe the
etiology of this major public health problem
in a sub-Saharan African population. 
Materials and Methods
Study population. The study population was
recruited as a part of the Gambia Liver Cancer
Study as described previously (Kirk et al.
2004). Brieﬂy, individuals with suspected liver
disease were recruited from the liver disease
referral clinics of three tertiary hospitals in
The Gambia [Royal Victoria Hospital (RVH),
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BACKGROUND: Cirrhosis of the liver is thought to be a major cause of morbidity and mortality in
sub-Saharan Africa, but few controlled studies on the etiology of cirrhosis have been conducted in
this region. 
OBJECTIVES: We aimed to elucidate the association between environmental and infectious expo-
sures and cirrhosis in The Gambia. 
METHODS: Ninety-seven individuals were diagnosed with cirrhosis using a validated ultrasound
scoring system and were compared with 397 controls. Participants reported demographic and food
frequency information. Blood samples were tested for hepatitis B surface antigen (HBsAg), hepati-
tis B e antigen (HBeAg), hepatitis C virus (HCV) antibody, HCV RNA, and the aﬂatoxin-associ-
ated 249ser TP53 mutation.
RESULTS: HBsAg seropositivity was associated with a signiﬁcant increase in risk of cirrhosis [odds
ratio (OR) = 8.0; 95% conﬁdence interval (CI), 4.4–14.7] as was the presence of HBeAg (OR =
10.3; 95% CI, 2.0–53.9) and HCV infection (OR = 3.3; 95% CI, 1.2–9.5). We present novel data
that exposure to aﬂatoxin, as assessed both by high lifetime groundnut (peanut) intake and by the
presence of the 249ser TP53 mutation in plasma, is associated with a signiﬁcant increase in the risk
for cirrhosis (OR = 2.8; 95% CI, 1.1–7.7 and OR = 3.8; 95% CI, 1.5–9.6, respectively).
Additionally, aﬂatoxin and hepatitis B virus exposure appeared to interact synergistically to sub-
stantially increase the risk of cirrhosis, although this was not statistically signiﬁcant. 
CONCLUSIONS: Our results suggest that the spectrum of morbidity associated with aﬂatoxin exposure
could include cirrhosis.
KEY WORDS: aﬂatoxin, Africa, hepatitis B virus, liver cirrhosis, p53, The Gambia, ultrasound. Environ
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[Online 10 July 2008]Banjul; Medical Research Council Hospital
(MRC), Fajara; and Bansang Hospital (BSG),
Bansang]. Recruitment occurred between
September 1997 and January 2001. After
informed consent, study participants with sus-
pected liver disease were administered a ques-
tionnaire by an interviewer, underwent
standardized clinical and ultrasound exams,
and provided a blood sample. The question-
naire assessed demographic, medical history,
food consumption, and lifestyle characteristics.
All questionnaire, clinical, and ultrasound
information was recorded on standardized
reporting forms. All ultrasound examinations
were performed by physicians trained in liver
ultrasonography; periodic retraining and
selected duplicate testing by examiners were
performed to ensure consistency.
Individuals without suspected liver disease
were recruited from the outpatient clinics of
the same three hospital sites to serve as a con-
trol group. These participants were frequency-
matched to suspected liver disease patients by
age (10-year groupings) and sex. Participants
without suspected liver disease were adminis-
tered the identical interviewer-administered
questionnaire, underwent a standardized clini-
cal examination to identify signs of underlying
liver disease, and provided a blood sample.
Local and international scientiﬁc and ethical
review committees approved the study proto-
col, and informed consent was obtained from
each participant before inclusion in the study.
Case and control definitions. Individuals
with suspected liver disease recruited from the
liver disease referral clinics were classified as
having liver cirrhosis (cases) if they had a)n o
evidence of space-occupying hepatic lesions by
ultrasound examination; b) no evidence for
alternative diagnoses (e.g., congestive heart fail-
ure, abdominal tuberculosis); c) complete
demographic and hepatitis B surface antigen
(HBsAg) information; and d) a score of 7 of a
possible 11 points on the ultrasound-based cir-
rhosis scale developed by Lin et al. (1993).
This scale has a 77.8% sensitivity and 92.5%
speciﬁcity versus liver biopsy to classify HBV-
infected patients as having cirrhosis (Hung
et al. 2003) and is increasingly used as a non-
invasive mechanism to diagnose cirrhosis
(Iloeje et al. 2006). Individuals without sus-
pected liver disease recruited from the out-
patient clinics were classiﬁed as controls if they
had a) alpha-fetoprotein (AFP) levels in the
normal range (< 20 ng/mL); b) no evidence of
underlying liver disease on the standardized
clinical exam; and c) complete demographic
and HBsAg information.
Laboratory testing. Blood specimens were
processed promptly after collection and stored
at either –20°C or –70°C, depending on the
testing planned for each aliquot. HBsAg was
determined as a marker of chronic HBV car-
riage by a reverse passive hemagglutination
assay (Murex Diagnostics Limited, Dartford,
UK) with radioimmunoassay testing of nega-
tive samples (Sorin Biomedica Diagnostics,
Vercelli, Italy). Participants positive for
HBsAg were tested for hepatitis B e antigen
(HBeAg) using a radioimmunoassay kit
(DiaSorin SA, Sallugia, Italy). HCV antibody
status (anti-HCV) was determined by third-
generation enzyme-linked immunosorbent
assay (ELISA; ORTHO Clinical Diagnostics,
Neckargemund, Germany). Samples that were
seroreactive by ELISA to HCV were screened
with a recombinant immunoblot assay (RIBA
HCV 3.0 SIA; Chiron, Emeryville, CA, USA)
and for HCV RNA using a real-time reverse
transcription-polymerase chain reaction
(RT-PCR) assay as described previously
(Zhang et al. 2006). We defined individuals
who tested positive on either the RIBA assay
or the RT-PCR assay as being HCV-positive.
AFP was detected and quantiﬁed by standard
radiometric assay methods (DiaSorin).
Detection of the 249ser TP53 mutation.
Previous investigations have demonstrated that
the 249ser TP53 mutation is a biomarker of the
aflatoxin-associated mutational effect in the
p53 gene (Aguilar et al. 1993; Mace et al.
1997); methods for detection of the 249ser
TP53 mutation in plasma have been previously
described (Kirk et al. 2000, 2005; Szymanska
et al. 2004). Brieﬂy, circulating cell-free DNA
was extracted from 200 µL plasma using
QiAmp DNA Blood Mini Kit (Qiagen,
Hilden, Germany) according to the manufac-
turer’s protocol. Puriﬁed DNA was eluted and
resuspended, and exon 7 of the TP53 gene was
ampliﬁed. PCR products underwent restriction
digestion (HaeIII) followed by automated
sequencing (AbiPrism 3100; PerkinElmer,
Waltham, MA, USA). All samples underwent
two independent analyses, and discordant
results underwent a third analysis. At all steps,
a series of controls without DNA template was
used to rule out contamination.
Statistical analysis. We calculated descrip-
tive statistics for questionnaire and laboratory
variables among case and control participants
using t-tests, asymptotic chi-square tests, and
Fisher’s exact tests to test for differences
between study groups. Logistic regression
models were used to evaluate potential risk
factors for cirrhosis in cases compared with
controls. To minimize any potential effect of
including occult HCC within our cirrhotic
cases, we performed separate analyses exclud-
ing cirrhosis cases with significantly elevated
AFP levels (> 500 ng/mL); however, our ﬁnd-
ings were not substantively changed (data not
shown). We evaluated markers of viral hepati-
tis infection alone and with adjustment for
age, sex, recruitment site and date, socio-
economic status (e.g., education, household
floor type), smoking, alcohol consumption,
and other viral markers. 
Dietary and molecular markers of aﬂatoxin
exposure, both alone and with adjustment for
potential confounding factors, were evaluated
as possible risk factors for cirrhosis. Self-
reported dietary exposure to aﬂatoxin was con-
structed from the dietary questionnaire. Study
participants were asked about their consump-
tion of groundnuts in the past 2 months and
whether this consumption was greater, less, or
about the same as during the entirety of their
lives. Previously, we demonstrated that per-
sons with clinical liver disease often decrease
their dietary intake as well as reduce exposure
to risk factors suspected to be associated with
the disease (Kirk et al. 2005); therefore, life-
time rather than 2-month groundnut intake
was considered the primary dietary exposure
variable. Lifetime groundnut consumption
was determined by adjusting the level of
2-month groundnut consumption up one
level of consumption, or down one level of
consumption for those individuals who
reported decreased or increased lifetime con-
sumption relative to recent intake, respec-
tively. We used this variable for trend analysis,
but collapsed this variable into three levels of
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Table 1. Characteristics of the study participants
(controls, n = 397; cirrhosis cases, n = 97).
Controls Cirrhosis cases 
Characteristic [no. (%)] [no. (%)]
Sex
Male 282 (71.0) 61 (62.9)
Female 115 (29.0) 36 (37.1)
Site*
RVH 107 (27.0) 51 (52.6)
MRC 102 (25.7) 21 (21.7)
BSG 188 (47.4) 25 (25.8)
Age group (years)
< 35 125 (31.5) 31 (32.0)
35–44 76 (19.1) 21 (21.7)
45–54 72 (18.1) 24 (24.7)
55–64 76 (19.1) 15 (15.5)
≥ 65 48 (12.1) 6 (6.2)
Recruitment timing
November–January 98 (24.7) 30 (30.9)
February–April 88 (22.2) 23 (23.7)
May–July 84 (21.2) 26 (26.8)
August–October 127 (32.0) 18 (18.6)
Ethnic group*
Mandinka 130 (32.8) 24 (24.8)
Fula 82 (20.7) 31 (32.0)
Wollof 60 (15.1) 23 (23.7)
Other 125 (31.5) 19 (19.6)
Education*
Ever school 353 (88.9) 77 (79.4)
None 44 (11.1) 20 (20.6)
Earth ﬂoor in residence
Yes 197 (49.6) 59 (60.8)
No 200 (50.4) 38 (39.3)
Regular tobacco use
Cigarettes  163 (41.1) 36 (37.1)
Pipe 25 (6.3) 7 (7.2)
Chewing/snuff 18 (4.3) 8 (8.3)
Regular alcohol use 33 (8.3) 8 (8.3)
Age [years (mean ± SD)] 44.8 ± 15.2  42.5 ± 14.1
Cigarette pack-years  7.4 ± 16.2  5.5 ± 12.0
(mean ± SD)
*p < 0.05 compared with controls in that location or group. exposure in our evaluations of risk. Similar to
the dietary exposure variables, short-term bio-
markers of aﬂatoxin exposure such as urinary
adducts or serum aﬂatoxin–albumin adducts
can be affected by the severity of liver disease
in a case–control study design (Hall and Wild
1994). Therefore, we evaluated plasma 249ser
TP53 mutations, which, although perhaps less
sensitive, would be reﬂective of the biological
effects of longer-term aﬂatoxin exposure and
be less susceptible to changes with illness. The
plasma 249ser TP53 mutation was detected
more often among individuals with higher lev-
els of lifetime groundnut consumption, but
this association did not attain statistical signiﬁ-
cance (exact p = 0.10). Therefore, although
related, the dietary and molecular markers rep-
resent different measures of aﬂatoxin exposure;
we used separate models for analysis of each
aﬂatoxin marker.
We evaluated interactions between afla-
toxin exposure and HBV infection through
participant stratiﬁcation and subsequent logis-
tic regression analysis, as well as through
incorporation of ﬁrst-order interaction terms
into the logistic regression models. All analy-
ses were conducted using SAS version 9.1
(SAS Institute, Inc., Cary, NC, USA).
Results
Characteristics of the study participants. After
excluding liver-disease referral patients with
space-occupying lesions on ultrasonography
characteristic of HCC or with alternative diag-
noses other than liver disease (Kirk et al.
2004), a total of 111 persons with suspected
liver cirrhosis were identified. Of these, two
were not tested for HBsAg. Of the remaining
109 individuals, 97 had a score of ≥ 7 on the
ultrasound-based cirrhosis scale of Lin et al.
(1993) and were classified as cirrhosis cases.
Of 408 control participants recruited, 397 had
no evidence of underlying liver disease, AFP
levels in the normal range, and complete
HBsAg and demographic information and
were included in this analysis. 
Characteristics of the 97 cirrhosis cases and
397 controls are listed in Table 1. Of the case
and control participants, mostly male, they
often lived in homes with dirt ﬂoors, and they
were recruited throughout the year and from
all adult age brackets. The mean age of cir-
rhotic patients was 42.5 years compared with
44.8 years for controls. Cirrhotic patients dif-
fered from control participants with regard to
recruitment site and ethnicity and were less
likely to have attended school. 
HBV and HCV infection and cirrhosis
risk. Table 2 shows markers of HBV and HCV
infection among cirrhosis cases and controls, as
well as unadjusted and adjusted odds ratios
(ORs) for cirrhosis. HBsAg seropositivity was
very common among the cirrhosis cases
(58.8%) and highly associated with cirrhosis
[adjusted OR = 8.0; 95% conﬁdence interval
(CI), 4.4–14.7]. Individuals who were HBeAg-
positive had a 10-fold higher risk of cirrhosis
than persons without chronic HBV infection.
HCV infection was identiﬁed in 9.3% of cir-
rhotic cases and was associated with a > 3-fold
higher risk of cirrhosis compared with HCV-
uninfected persons.
Aflatoxin exposure and cirrhosis risk.
Eighty cirrhosis cases and 327 controls pro-
vided information regarding groundnut con-
sumption on the study questionnaire. In
addition, 78 cirrhosis cases and 346 controls
were evaluated for plasma 249ser TP53 muta-
tions. Table 3 shows the distribution of life-
time groundnut consumption and of 249ser
TP53 mutations among cirrhosis cases and
controls, as well as unadjusted and adjusted
ORs evaluating the association between aﬂa-
toxin exposure variables and cirrhosis.
Increasing lifetime groundnut intake was asso-
ciated with a signiﬁcant increase in the risk of
cirrhosis (p-trend = 0.01). Moderate and high
lifetime groundnut consumption versus low
consumption was associated with an almost
2-fold and signiﬁcant 3-fold increase in risk of
cirrhosis, respectively. The presence of the
plasma 249ser TP53 mutation conferred a sta-
tistically signiﬁcant almost 4-fold increase in
risk of cirrhosis in this population.
Interaction between HBV infection and
aﬂatoxin exposure. Table 4 shows the separate
and joint distribution of HBV and aflatoxin
markers among cirrhosis cases and controls, as
well as adjusted ORs evaluating the association
with cirrhosis. Compared to persons with low-
to-moderate groundnut intake that were
HBsAg-negative, the risk of cirrhosis was
increased 1.7-fold with high groundnut intake
alone, > 8-fold with HBsAg-positivity alone,
and almost 27-fold in individuals with both
exposures present. As seen in Table 4, the risk
of cirrhosis increased almost 2-fold with
expression of the 249ser TP53 mutation alone
and > 7-fold with HBsAg positivity, but was
46-fold higher for persons expressing both
compared with individuals who lacked either
marker. The statistical term for the interaction
between HBsAg and either lifetime groundnut
intake or the 249ser TP53 mutation variables
did not attain signiﬁcance (p = 0.37 and 0.35,
respectively). 
Aflatoxin in etiology of cirrhosis in West Africa
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Table 2. HBV and HCV infection and association with cirrhosis (controls, n = 397; cirrhosis cases, n = 97).
Controls Cirrhosis  cases Unadjusted Adjusteda
[no. (%)] [no. (%)] [OR (95% CI)] [OR (95% CI)]
HBV status
HBsAg (–) 336 (84.6) 40 (41.2) Referent Referent
HBsAg (+) 61 (15.4) 57 (58.8) 7.8 (4.8–12.8) 8.0 (4.4–14.7)
HBsAg (+)/HBeAg (+) 2 (0.5) 15 (15.5) 36.1 (8.1–161.0) 10.3 (2.0–53.9)
HCV status
HCV (–) 381 (96.0) 88 (90.7) Referent Referent
HCV (+) 16 (4.0) 9 (9.3) 2.4 (1.0–5.7) 3.3 (1.2–9.5)
aAdjusted for age, sex, recruitment site and date, education, household ﬂoor type, tobacco, alcohol, HBV, and HCV variables. 
Table 3. Exposure to aﬂatoxin and association with cirrhosis. 
Controls Cirrhosis cases Unadjusted Adjusteda
[no. (%)] [no. (%)] [OR (95% CI)] [OR (95% CI)]
Lifetime groundnut intake  n = 327 n = 80
Low 68 (21) 10 (13) Referent Referent
Moderate 189 (58) 43 (54) 1.6 (0.7–3.3) 1.7 (0.7–4.2)
High 70 (21) 27 (34) 2.6 (1.2–5.8) 2.8 (1.1–7.7)
249ser TP53 mutation n = 346 n = 78
Absent 329 (95) 65 (83) Referent Referent
Present 17 (5) 13 (17) 3.9 (1.8–8.4) 3.8 (1.5–9.6)
aAdjusted for age, sex, recruitment site and date, education, household ﬂoor type, alcohol, tobacco, HBV, and HCV variables. 
Table 4. Joint effect of HBV infection and aﬂatoxin exposure and association with cirrhosis.
Controls (n = 327) Cirrhosis cases  Adjusteda
[no. (%)] [no. (%)] [OR (95% CI)]
HBV and lifetime groundnut intake status n = 327 n = 80
HBsAg (–)/High intake (–) 218 (67) 25 (31) Referent
HBsAg (–)/High intake (+) 62 (19) 12 (15) 1.7 (0.7–4.1)
HBsAg (+)/High intake (–) 39 (12) 28 (35) 8.1 (3.9–17.1)
HBsAg (+)/High intake (+) 8 (2) 15 (19) 26.8 (8.7–82.1)
HBV and 249ser TP53 status n = 346 n = 78
HBsAg (–)/249ser TP53 (–) 284 (82) 29 (37) Referent
HBsAg (–)/249ser TP53 (+) 15 (4) 4 (5) 1.8 (0.5–6.7)
HBsAg (+)/249ser TP53 (–) 45 (13) 36 (46) 7.3 (3.9–13.6)
HBsAg (+)/249ser TP53 (+) 2 (0.6) 9 (12) 46.0 (8.5–249.1)
aAdjusted for age, sex, recruitment site and date, education, household ﬂoor type, alcohol, tobacco, and HCV variables. Discussion
Despite the postulated heavy burden of disease,
remarkably little descriptive risk factor or natu-
ral history data have been published on chronic
liver disease or cirrhosis from sub-Saharan
African populations (Lesi et al. 2002; Lin et al.
2005). In this study, we found that chronic
HBV infection and aﬂatoxin exposure, either
separately or in synergy, were the etiologic
agents likely responsible for most cirrhosis cases
identiﬁed in this West African study popula-
tion. Our results suggest that the spectrum of
morbidity associated with aflatoxin exposure
could include cirrhosis. 
The impact of aﬂatoxin on human health
is substantial and has been documented in
both acute and chronic exposure settings
(Groopman et al. 2008; Strosnider et al.
2006). Acute exposure to high levels of afla-
toxin (aﬂatoxicosis) can result in acute toxicity,
which often presents clinically as fulminant
liver failure. For example, a recent outbreak of
acute aﬂatoxicosis from contaminated maize in
Kenya resulted in 125 human deaths, signiﬁ-
cant mortality among domesticated livestock,
and widespread socioeconomic impact (Lewis
et al. 2005). The health impacts of chronic
aﬂatoxin exposure are equally serious. A large
body of experimental, clinical, and epidemio-
logic evidence has deﬁned aﬂatoxin as one of
the most potent naturally occurring hepatocar-
cinogens; chronic exposure to moderate or
even low levels of aﬂatoxin has been linked to
development of HCC (IARC 1993). Chronic
aﬂatoxin exposure has also been associated with
impaired growth and perturbations in meas-
ures of immune function in young West
African children (Gong et al. 2004; Turner
et al. 2003). However, data regarding other
potential health effects of chronic aflatoxin
exposure are scarce, resulting in signiﬁcant lim-
itation of current research (Strosnider et al.
2006). Primary limitations for conducting this
research include difﬁculties in deﬁning clinical
outcomes in often remote or resource-
constrained environments and difficulty in
accurately assessing aﬂatoxin exposure. 
Although standardized clinical scoring
systems, such as the Child-Pugh score, have
for decades been accepted for assessing the
severity of liver cirrhosis, numerous recent
reports have increasingly focused on the util-
ity of noninvasive methods and clinical pre-
diction models to diagnose fibrosis and
cirrhosis (Schneider et al. 2005; Shen et al.
2006; Yamada et al. 2006). However, most of
these studies to date have been conducted
among HCV-infected populations in indus-
trialized countries. In the present study we
used a validated, reproducible, and non-
invasive diagnostic method to diagnose cir-
rhosis in a setting where an etiologic study of
risk factors for biopsy-diagnosed liver cirrho-
sis would not have been possible. The
presence of encephalopathy or marked ascites
precluded biopsy in some study participants,
and resources for rapidly performing pre-
biopsy screening laboratories were not consis-
tently available at the three recruitment sites.
Furthermore, participant acceptance of ultra-
sound was excellent, and potentially serious
postbiopsy complications were summarily
avoided. Last, given that the speciﬁcity of the
ultrasound scoring system used in this study is
> 90% among HBV-infected subjects (Hung
et al. 2003), we believe that noninvasive
methods for measuring liver ﬁbrosis and diag-
nosing cirrhosis hold significant promise for
increasing clinical and research capabilities in
African settings.
Currently there is no gold standard
methodology available to measure cumulative
lifetime aflatoxin exposure. In lieu of a gold
standard, we used two different approaches to
assess exposure to aﬂatoxin during the period
of time that we hypothesized would have etio-
logic signiﬁcance for the development of cir-
rhosis. First, we evaluated self-reported lifetime
intake of groundnuts, the primary food com-
ponent contributing to aﬂatoxin exposure in
The Gambia (Wild et al. 1993, 2000).
Questionnaire-derived data have been vali-
dated for assessment of many dietary compo-
nents; however, this information is obviously
dependent on participant recall for its validity.
Second, we evaluated a laboratory-based bio-
marker potentially reflecting the biological
effect of aflatoxin exposure. The presence of
the 249ser TP53 mutation, associated with aﬂa-
toxin exposure in experimental systems
(Aguilar et al. 1993; Mace et al. 1997), is com-
monly observed in HCC patients from high
aﬂatoxin exposure regions (Aguilar et al. 1994)
and is strongly associated with HCC in case–
control and prospective epidemiologic studies
(Jackson et al. 2003; Kirk et al. 2000, 2005).
However, recent experimental data suggest that
aﬂatoxin exposure alone may not be sufﬁcient
to induce 249ser TP53 mutations (Tong et al.
2006) and that other cofactors such as HBV
infection (Sohn et al. 2000) or host factors
(Mace et al. 1997) may modulate the muta-
genic capacity of aﬂatoxin. In addition, because
detection occurs in plasma DNA, it is unclear
if advanced liver disease impacts release of the
mutation. Finally, levels of the 249ser TP53
mutation in plasma exhibit seasonal variability
(Lleonart et al. 2005), suggesting that this
marker may partly reﬂect shorter-term effects
of aﬂatoxin exposure. Longitudinal studies to
determine marker stability over time and the
effect of liver disease severity on detection are
needed; these issues are the subject of ongoing
investigations in The Gambia. Despite these
limitations, we believe that the 249ser TP53
mutation represents the best biomarker cur-
rently available to assess the biological effect of
cumulative aﬂatoxin exposure. 
Both measures of aﬂatoxin exposure evalu-
ated as a part of this study were associated with
a significant increase in the risk of cirrhosis.
Our results also suggest that aﬂatoxin exposure
and chronic HBV infection may interact syner-
gistically to increase the risk of cirrhosis
notably above and beyond that expected for
two independent hepatotoxins. The mecha-
nisms by which aflatoxin is activated and
induces HCC-associated mutational changes
have been well characterized (Wild and Turner
2002), but less well understood is the impact
of aflatoxin on the development of cirrhosis
and precancerous architectural changes in the
liver. Empirical evidence of AFB1-induced
fibrosis and cirrhosis in humans has thus far
been limited (Aguilar et al. 1994), but animal
studies have found significantly more liver
ﬁbrosis among animals experimentally inocu-
lated with aﬂatoxin than uninoculated control
animals (Ortatatli et al. 2005; Seffner et al.
1997). In addition, although significant
progress has been made with regard to under-
standing the mechanisms of interaction
between aﬂatoxin and HBV in hepatocarcino-
genesis (Kew 2003), it is not clear whether
these proposed mechanisms will explain the
interaction between aﬂatoxin and HBV in the
etiology of cirrhosis.
As expected, we found HBsAg positivity
to be a signiﬁcant risk factor for cirrhosis; we
have extended this work to document a fur-
ther increase in risk of cirrhosis associated
with HBeAg seropositivity. Similarly, we
found HCV infection to be a signiﬁcant risk
factor for cirrhosis, although the magnitude
of this risk was lower than that conferred by
HBsAg positivity. Notably, the average age of
HCV-related cirrhosis patients was around
15 years older than HBV-related patients,
consistent with the premise of a different
natural history of infection between the two
viruses in West Africa (for further discussion,
see Kirk et al. 2004, 2006). In contrast, we
observed no significant associations between
alcohol and tobacco exposure and cirrhosis
(data not shown). The low overall prevalence
and limited societal acceptance of alcohol
consumption in this majority Muslim coun-
try may offer some explanation for these ﬁnd-
ings. Also, given that a signiﬁcant association
between tobacco exposure and cirrhosis has
been only rarely observed to our knowledge
(Tsai et al. 2003), it is possible that exposure
to tobacco use conveys no increase or only a
slight increase in risk of cirrhosis. 
Cirrhosis of the liver is a major cause of
morbidity and mortality in sub-Saharan
Africa. Using a validated ultrasound scoring
system to diagnose cirrhosis, we confirmed
associations with chronic HBV and HCV
infections and further provide evidence
that aﬂatoxin may also be an etiologic factor
for cirrhosis. As such, expanded access to 
Kuniholm et al.
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tinued development of aflatoxin-reduction
intervention programs (Groopman et al.
2008; Strosnider et al. 2006; Turner et al.
2005) could substantially decrease the burden
of chronic liver disease in this region.
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